VPA does not enhance platinum binding to DNA in cisplatin-resistant neuroblastoma cancer cells
Open Access
- 25 September 2017
- journal article
- research article
- Published by IOS Press in Tumor Biology
- Vol. 39 (9)
- https://doi.org/10.1177/1010428317711656
Abstract
Neuroblastoma represents a malignancy of the sympathetic nervous system characteristic by biological heterogeneity. Thus, chemotherapy exhibits only low effectivity in curing high-risk forms. Previous studies revealed the cytotoxic potential of valproate on neuroblastoma cells. Nevertheless, these studies omitted effects of hypoxia, despite its undeniable tumorigenic role. In this study, we addressed the question whether valproate promotes binding of platinum-based anti-cancer drugs (cisplatin, carboplatin and oxaliplatin) to DNA and role of hypoxia, cellular antioxidant capacity and cisplatin resistance in this process. Following parameters differed significantly when cells were exposed to treatment with platinum-based drugs: elevation of platinum content bound to DNA, elevation of total thiol content, GSH/GSSG ratio, glutathione reductase and peroxidase, superoxide dismutase and elevation of antioxidant capacity. Hypoxia caused a decrease in cytosine/adenine peak, and no changes in platinum–DNA binding properties were observed. After valproate co-treatment, oxidative stress–related parameters and cytosine/adenine peak were only elevated. The amount of platinum bound to DNA was not changed significantly. Valproate is not able to enhance platinum binding to DNA in neuroblastoma cells, neither in case of intrinsic resistance (UKF-NB-4) nor in case of acquired resistance (UKF-NB-4CDDP). Therefore, another mechanism different from increase in platinum binding to DNA should be considered as a synergistic effect of valproate by cisplatin treatment.Keywords
This publication has 34 references indexed in Scilit:
- Automated assay of the potency of natural antioxidants using pipetting robot and spectrophotometryJournal of Applied Biomedicine, 2012
- Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic ChangesPharmacological Reviews, 2012
- Valproic acid overcomes hypoxia-induced resistance to apoptosisOncology Reports, 2011
- Novel trans-platinum complexes of the histone deacetylase inhibitor valproic acid; synthesis, in vitro cytotoxicity and mutagenicityJournal of Inorganic Biochemistry, 2011
- Glutathione depletion by valproic acid in sandwich-cultured rat hepatocytes: Role of biotransformation and temporal relationship with onset of toxicityToxicology and Applied Pharmacology, 2011
- The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cellsJournal of Gynecologic Oncology, 2010
- Hypoxia induces a novel signature of chromatin modifications and global repression of transcriptionMutation research. Reviews in mutation research, 2008
- Recognition and processing of cisplatin- and oxaliplatin-DNA adductsCritical Reviews in Oncology/Hematology, 2005
- Chemotherapy-induced Apoptosis of S-type Neuroblastoma Cells Requires Caspase-9 and Is Augmented by CD95/Fas StimulationOnline Journal of Public Health Informatics, 2004
- Association of Multiple Copies of the N-mycOncogene with Rapid Progression of NeuroblastomasThe New England Journal of Medicine, 1985